# Christian Grohé
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/christian-grohe/
## Facts
| Field | Value |
| --- | --- |
| Citations | 19,771 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 60 |
| i10-index | 172 |
| Last Known Institution | DRK Kliniken Berlin |
| OpenAlex ID | https://openalex.org/A5114929422 |
| ORCID iD | 0000-0003-2724-7647 |
| Works | 436 |
## Researcher papers
Showing 12 of 14.
- [Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-plus-platinum-etoposide-versus-platinum-etoposide-in-first-line/)
- [Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-resected-i-egfr-i-mutated-non-small-cell-lung-cancer/)
- [Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial](https://scholariq.org/papers/activity-and-safety-of-nivolumab-an-anti-pd-1-immune-checkpoint-inhibitor-for/)
- [Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/durvalumab-with-or-without-tremelimumab-plus-platinum-etoposide-versus-platinum/)
- [Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-resected-i-egfr-i-mutated-nsclc/)
- [Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial](https://scholariq.org/papers/pirfenidone-in-patients-with-progressive-fibrotic-interstitial-lung-diseases/)
- [Modulation of Antioxidant Enzyme Expression and Function by Estrogen](https://scholariq.org/papers/modulation-of-antioxidant-enzyme-expression-and-function-by-estrogen/)
- [Estrogen Receptor α Rapidly Activates the IGF-1 Receptor Pathway](https://scholariq.org/papers/estrogen-receptor-rapidly-activates-the-igf-1-receptor-pathway/)
- [Elderly patients diagnosed with idiopathic pulmonary arterial hypertension: Results from the COMPERA registry](https://scholariq.org/papers/elderly-patients-diagnosed-with-idiopathic-pulmonary-arterial-hypertension/)
- [Estrogen Modulates AT1Receptor Gene Expression In Vitro and In Vivo](https://scholariq.org/papers/estrogen-modulates-at-sub-1-sub-receptor-gene-expression-in-vitro-and-in-vivo/)
- [Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial](https://scholariq.org/papers/adjuvant-osimertinib-for-resected-egfr-mutated-stage-ib-iiia-non-small-cell-lung/)
- [Phenotypes of organ involvement in sarcoidosis](https://scholariq.org/papers/phenotypes-of-organ-involvement-in-sarcoidosis/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis](https://scholariq.org/topics/interstitial-lung-diseases-and-idiopathic-pulmonary-fibrosis/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Sarcoidosis and Beryllium Toxicity Research](https://scholariq.org/topics/sarcoidosis-and-beryllium-toxicity-research/)
## Researcher university
- [DRK Kliniken Berlin](https://scholariq.org/institutions/drk-kliniken-berlin/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.